News

Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a ...
Investor's Business Daily on MSN4h
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
Generic drugs had a "stable" performance in the second quarter, with global revenue down about 2% in local currency.
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.
Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid
The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...